GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (LSE:0HKE) » Definitions » Cyclically Adjusted Price-to-FCF

Novartis AG (LSE:0HKE) Cyclically Adjusted Price-to-FCF : (As of May. 11, 2024)


View and export this data going back to . Start your Free Trial

What is Novartis AG Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Price-to-FCF Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.49 19.15 17.79 17.74 18.20

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.27 18.32 18.84 18.20 18.65

Competitive Comparison of Novartis AG's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted Price-to-FCF falls into.



Novartis AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.353/106.4611*106.4611
=0.353

Current CPI (Mar. 2024) = 106.4611.

Novartis AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.569 101.517 0.597
201409 0.748 101.247 0.787
201412 1.129 100.704 1.194
201503 0.268 100.339 0.284
201506 0.485 100.464 0.514
201509 0.619 99.785 0.660
201512 0.861 99.386 0.922
201603 0.236 99.475 0.253
201606 0.693 100.088 0.737
201609 0.711 99.604 0.760
201612 0.910 99.380 0.975
201703 0.488 100.040 0.519
201706 0.957 100.285 1.016
201709 0.885 100.254 0.940
201712 0.872 100.213 0.926
201803 0.533 100.836 0.563
201806 1.052 101.435 1.104
201809 0.993 101.246 1.044
201812 0.995 100.906 1.050
201903 0.601 101.571 0.630
201906 0.852 102.044 0.889
201909 1.306 101.396 1.371
201912 0.896 101.063 0.944
202003 0.668 101.048 0.704
202006 1.134 100.743 1.198
202009 0.789 100.585 0.835
202012 0.897 100.241 0.953
202103 0.371 100.800 0.392
202106 1.019 101.352 1.070
202109 1.291 101.533 1.354
202112 1.010 101.776 1.056
202203 0.242 103.205 0.250
202206 1.042 104.783 1.059
202209 1.517 104.835 1.541
202212 1.199 104.666 1.220
202303 0.856 106.245 0.858
202306 0.826 106.576 0.825
202309 1.534 106.570 1.532
202312 0.564 106.461 0.564
202403 0.353 106.461 0.353

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (LSE:0HKE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Novartis AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (LSE:0HKE) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (LSE:0HKE) Headlines

No Headlines